In vivo experiments testing whether direct targeting of Axl, Mertk or Tyro3 by using specific TAM inhibitors or by GAS6 neutralizing antibodies can reduce the development of hepatic fibrosis are still underway. The gene discussed is GAS6; the disease is Hepatic fibrosis.